Guest Columns & From The Editor

31. In Vivo CAR T Needs More Than Better Cell Engineering 8/26/2026

    In vivo CAR T’s potential to expand access and simplify manufacturing hinges on targeted LNP delivery and solving the durability challenge.

32. Enzyme Activity As A Surrogate Potency Marker In Cell Therapy 8/26/2026

    When measuring cell therapy potency, biochemical assays can provide a rapid alternative to the time- and material-consuming standard of cell-based assays.

33. Implementing And Optimizing Your eQMS 8/25/2026

    This article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.

34. Novel Approach To Cancer Explores Severing Its Genetic Supply Line 8/25/2026

    Gene ablation represents an important and novel approach to treating cancer. One company is focusing on disabling the NRF2 gene to starve cancer cells.

35. Choosing Analytical Technologies At The Right Stage Of Development 8/24/2026

    Take a beat before investing in the latest analytical tools. Capability and sensitivity come at a cost. Depending on your phase, you might not need it just yet.

36. CDMO Selection For Small Biotech: Amit Jain On Avoiding Costly Transfers 8/20/2026

    Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.

37. Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs 8/20/2026

    CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.

38. Unlocking The Future Of Cell And Gene Therapies 8/19/2026

    We took the opportunity to speak with some BioPhorum members about issues such as emerging technologies, regulatory challenges, and engagement with regulators in the advanced therapy medicinal products (ATMP) space.

39. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

    Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

40. What Goes Into Restarting A Shelved Orphan Drug Candidate? 8/19/2026

    The Orphan Therapeutics Accelerator wants to help viable clinical-phase products reach patients. Its cofounder describes the complexity of rebooting a shelved candidate.